GASTROENTEROPANCREATIC NEUROENDOCRINE CARCINOMA (GEP-NEC)

Clinical trials for GASTROENTEROPANCREATIC NEUROENDOCRINE CARCINOMA (GEP-NEC) explained in plain language.

Never miss a new study

Get alerted when new GASTROENTEROPANCREATIC NEUROENDOCRINE CARCINOMA (GEP-NEC) trials appear

Sign up with your email to follow new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE CARCINOMA (GEP-NEC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New hope for Tough-to-Treat cancers: first human trial of experimental drug begins

Disease control Recruiting now

This early-stage study is testing a new drug called PT217 for people with advanced neuroendocrine cancers that have spread or come back after standard treatments. Researchers will first find the safest dose of PT217 given alone, then test it combined with chemotherapy. The goal i…

Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE CARCINOMA (GEP-NEC)

Phase: PHASE1, PHASE2 • Sponsor: Phanes Therapeutics • Aim: Disease control

Last updated Mar 27, 2026 12:39 UTC

GASTROENTEROPANCREATIC NEUROENDOCRINE CARCINOMA (GEP-NEC)

Get alerted when new GASTROENTEROPANCREATIC NEUROENDOCRINE CARCINOMA (GEP-NEC) trials appear

New hope for Tough-to-Treat cancers: first human trial of experimental drug begins